NCT05205629

A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

A Real-world Clinical Study of Donafenib Combined With TACE as a Basis for the Treatment of Unresectable Hepatocellular Carcinoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, single-center, observational real-world study. It is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with Donafenib combined with TACE-based treatment, so as to observe and evaluate the efficacy and safety of Donafenib combined with TACE-based treatment in patients with unresectable HCC.

Conditions

• Hepatocellular Carcinoma
• Donafenib

Interventions

Type	Name	Description
DRUG	Donafenib combined with TACE	Donafenib(200mg bid po) combined with TACE

Timeline

• Start date: 2022-01-30
• Primary completion: 2024-01-30
• Completion: 2024-03-30
• First posted: 2022-01-25
• Last updated: 2022-03-23

Locations

1 site across 1 country: China